Analysis of the interaction between elderly people and a simulated virtual coach

The EMPATHIC project develops and validates new interaction paradigms for personalized virtual coaches (VC) to promote healthy and independent aging. To this end, the work presented in this paper is aimed to analyze the interaction between the EMPATHIC-VC and the users. One of the goals of the project is to ensure an end-user driven design, involving senior users from the beginning and during each phase of the project. Thus, the paper focuses on some sessions where the seniors carried out interactions with a Wizard of Oz driven, simulated system. A coaching strategy based on the GROW model was used throughout these sessions so as to guide interactions and engage the elderly with the goals of the project. In this interaction framework, both the human and the system behavior were analyzed. The way the wizard implements the GROW coaching strategy is a key aspect of the system behavior during the interaction. The language used by the virtual agent as well as his or her physical aspect are also important cues that were analyzed. Regarding the user behavior, the vocal communication provides information about the speaker's emotional status, that is closely related to human behavior and which can be extracted from the speech and language analysis. In the same way, the analysis of the facial expression, gazes and gestures can provide information on the non verbal human communication even when the user is not talking. In addition, in order to engage senior users, their preferences and likes had to be considered. To this end, the effect of the VC on the users was gathered by means of direct questionnaires. These analyses have shown a positive and calm behavior of users when interacting with the simulated virtual coach as well as some difficulties of the system to develop the proposed coaching strategy.The research presented in this paper is conducted as part of the project EMPATHIC that has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no 769872

A cross-cultural survey to identify Seniors’ preferences towards the Empathic Virtual Coach

The present investigation is part of the EMPATHIC project aiming at develop an Empathic Virtual Coach (VC) able to promote seniors' healthy lifestyle and independent aging. To this end, it is fundamental to investigate users' preferences towards the implemented automatic system refined on the basis of users' preferences derived from previous field trials with Wizard of Oz (WoZ) experimental sessions. Data collection has been carried out involving three different countries (France, Norway and Spain) and a total of 71 volunteers was enrolled in the planned field trials. Five Virtual Agents (VAs) named Natalie, Alice, Lena, Christian and Adam were purposely designed and users' preferences were assessed using the shortened version of the Virtual Agent Acceptance Questionnaire (VAAQ). This specific tool, developed by members of the EMPATHIC project, includes 7 different sections, and the present work aims to disseminate results of four of the seven sections administered to participants, devoted at assessing respectively: users' willingness to interact (section II); pragmatic, hedonic (Identity and Feeling) and attractiveness qualities (section III); the type of task participants entrusted to the proposed agents among healthcare, housework, protection/security, and front office jobs (section V) and agents voice' quality (section VI). Results reveal seniors' appreciation of agents' pleasantness, originality, voice' quality and ability to engage users in a long lasting interaction with them

Serial troponin-I and long-term outcomes in subjects with suspected acute coronary syndrome

BACKGROUND AND AIMS: It is unclear how serial high-sensitivity troponin-I (hsTnI) concentrations affect long-term prognosis in individuals with suspected acute coronary syndrome (ACS).METHODS: Subjects who underwent two hsTnI-measurements (Siemens TnI Flex® Reagent) separated by 1-7 hours, during a first-time hospitalization for myocardial infarction, unstable angina, observation for suspected myocardial infarction, or chest pain from 2012 through 2019, were identified through Danish national registries. Individuals were stratified per their hsTnI-concentration pattern (normal, rising, persistently elevated, or falling) and the magnitude of hsTnI-concentration change (&lt;20%,  &gt; 20 to 50%, or &gt;50% in either direction). We calculated absolute and relative mortality risks standardized to the distributions of risk factors for the entire study population.RESULTS: A total of 20,609 individuals were included of whom 2.3% had died at 30 days, and an additional 4.7% had died at 365 days. The standardized risk of death was highest among persons with a persistently elevated hsTnI-concentration (0-30 days: 8.0%, 31-365 days: 11.1%) and lowest among those with two normal hsTnI-concentrations (0-30 days: 0.5%, 31-365 days: 2.6%). In neither case did relative hsTnI-concentration changes between measurements clearly affect mortality risk. Among persons with a rising hsTnI-concentration pattern, 30-day mortality was higher in subjects with a &gt; 50% rise compared with those with a less pronounced rise (2.2% versus &lt;0.1%).CONCLUSIONS: Among individuals with suspected ACS, those with a persistently elevated hsTnI-concentration consistently had the highest risk of death. In subjects with two normal hsTnI-concentrations, mortality was very low and not affected by the magnitude of change between measurements.</p

Observational cohort study of rilpivirine (RPV) utilization in Europe

Altres ajuts: ViiV Healthcare LLC; Janssen Scientific Affairs; Janssen R&D; Bristol-Myers Squibb Company; Merck Sharp & Dohme Corp; Gilead Sciences; The Swiss National Science Foundation (148522); the Danish National Research Foundation and by the International Cohort Consortium of Infectious Disease (RESPOND) (DNRF126).Introduction: Data on safety and effectiveness of RPV from the real-world setting as well as comparisons with other NNRTIs such as efavirenz (EFV) remain scarce. Methods: Participants of EuroSIDA were included if they had started a RPV- or an EFV-containing regimen over November 2011-December 2017. Statistical testing was conducted using non-parametric Mann-Whitney U test and Chi-square test. A logistic regression model was used to compare participants' characteristics by treatment group. Kaplan-Meier analysis was used to estimate the cumulative risk of virological failure (VF, two consecutive values > 50 copies/mL). Results: 1,355 PLWH who started a RPV-based regimen (11% ART-naïve), as well as 333 initiating an EFV-containing regimen were included. Participants who started RPV differed from those starting EFV for demographics (age, geographical region) and immune-virological profiles (CD4 count, HIV RNA). The cumulative risk of VF for the RPV-based group was 4.5% (95% CI 3.3-5.7%) by 2 years from starting treatment (71 total VF events). Five out of 15 (33%) with resistance data available in the RPV group showed resistance-associated mutations vs. 3/13 (23%) among those in the EFV group. Discontinuations due to intolerance/toxicity were reported for 73 (15%) of RPV- vs. 45 (30%) of EFV-treated participants (p = 0.0001). The main difference was for toxicity of central nervous system (CNS, 3% vs. 22%, p 50 copies/mL and resistance in participants treated with RPV were similar to those reported by other studies. RPV safety profile was favourable with less frequent discontinuation due to toxicity than EFV (especially for CNS)